Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: Dose-effects and time-course

Drug and Alcohol Dependence

Volumn 123, Issue 1-3, 2012, Pages 57-65

  Bigelow, George E ^a   Preston, Kenzie L ^b   Schmittner, John ^b   Dong, Qunming ^c   Gastfriend, David R ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c ALKERMES INC   (United States)

Author keywords

Depot naltrexone; Extended release naltrexone; Hydromorphone; Injectable naltrexone; Naltrexone; Opioid blockade; Opioid challenge; Vivitrol

Indexed keywords

HYDROMORPHONE; NALTREXONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INJECTION SITE CONTUSION; INJECTION SITE INDURATION; INJECTION SITE REACTION; MALE; MULTICENTER STUDY; OPIATE ADDICTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUPIL REFLEX; RANDOMIZED CONTROLLED TRIAL; RESPONSE TIME; TREATMENT DURATION; VISUAL ANALOG SCALE;

ADULT; BLOOD PRESSURE; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; HYDROMORPHONE; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; NARCOTICS; OPIOID-RELATED DISORDERS; OXYGEN; PUPIL; RESPIRATORY RATE; SKIN TEMPERATURE; TIME FACTORS;

EID: 84861225663     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2011.10.018     Document Type: Article

References (25)

1. Bickel W.K., Stitzer M.L., Bigelow G.E., Liebson I.A., Jasinski D.R., Johnson R.E. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. J. Pharmacol. Exp. Ther. 1988, 247:47-53.
2. Comer S.D., Collins E.D., Kleber H.D., Nuwayser E.S., Kerrigan J.H., Fischman M.W. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology 2002, 159:351-360.
3. Comer S.D., Sullivan M.A., Yu E., Rothenberg J.L., Kleber H.D., Kampman K., Dackis C., O'Brien C.P. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 2006, 63:210-218.
4. ® naltrexone, a once a month long-acting injection, for the treatment of alcohol dependence. Front. Biosci. 2005, 10:643-655.
5. Dunbar J.D., Turncliff R.Z., Dong Q., Silverman B.L., Ehrich E.W., Lasseter K.C. Single and multiple dose pharmacokinetics of long-acting naltrexone. Alcohol. Clin. Exp. Res. 2006, 30:480-490.
6. Fram D.H., Marmo J., Holden R. Naltrexone treatment-the problem of patient acceptance. J. Subst. Abuse Treat. 1989, 6:119-122.
7. Garbutt J.C., Kranzler H.R., O'Malley S.S., Gastfriend D.R., Pettinati H.M., Silverman B.L., Loewy J.W., Ehrich E.W. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005, 293:1617-1625.
8. Gonzales J.P., Brogden R.N. Naltrexone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 1988, 35:192-213.
9. Harris K.M., Devries A., Dimidjian K. Trends in naltrexone use among members of a large private health plan. Psychiatr. Serv. 2004, 55:221-230.
10. Jasinski D.R., Preston K.L. Comparison of intravenously administered methadone, morphine and heroin. Drug Alcohol Depend. 1986, 17:301-310.
11. Johnson B.A., Ait-Daoud N., Aubin H.J., van den Brink W., Guzzetta R., Loewy J., Silverman B., Ehrich E. A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence. Alcohol. Clin. Exp. Res. 2004, 28:1356-1361.
12. Krupitsky E., Nunes E.V., Ling W., Illeperuma A., Gastfriend D.R., Silverman B.L. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 2011, 377:1506-1513.
13. Mark T.L., Kranzler H.R., Song X. Understanding US addiction physicians' low rate of naltrexone prescription. Drug Alcohol Depend. 2003, 71:219-228.
14. Martin W.R., Jasinski D.R., Mansky P.A. Naltrexone, an antagonist for the treatment of heroin dependence. Arch. Gen. Psychiatry 1973, 28:784-791.
15. Mello N.K., Mendelson J.H., Kuehnle J.C., Sellers M.S. Operant analysis of human heroin self-administration and the effects of naltrexone. J. Pharmacol. Exp. Ther. 1981, 216:45-54.
16. O'Malley S.S., Garbutt J.C., Gastfriend D.R., Dong Q., Kranzler H.R. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. J. Clin. Psychopharmacol. 2007, 27:507-512.
17. Preston K.L., Bigelow G.E., Liebson I.A. Butorphanol-precipitated withdrawal in opioid dependent human volunteers. J. Pharmacol. Exp. Ther. 1988, 2:441-448.
18. Resnick R., Volavka J., Freedman A.M., Thomas M. Studies of EN-1639 A (naltrexone): a new narcotic antagonist. Am. J. Psychiatry 1974, 131:646-650.
19. Shive M.S., Anderson J.M. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 1997, 28:5-24.
20. Strain E.C., Walsh S.L., Preston K.L., Liebson I.A., Bigelow G.E. The effects of buprenorphine in buprenorphine-maintained volunteers. Psychopharmacology 1997, 129:329-338.
21. Sullivan M.A., Vosburg S.K., Comer S.D. Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacology 2006, 189:37-46.
22. Turncliff R.Z., Dunbar J.L., Dong Q., Silverman B.L., Ehrich E.W., Dilzer S.C. Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment. J. Clin. Pharmacol. 2005, 45:1259-1267.
23. Walsh S.L., Sullivan J.T., Preston K.L., Garner J.E., Bigelow G.E. Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans. J. Pharmacol. Exp. Ther. 1996, 279:524-538.
24. Willette R. Narcotic Antagonists: The Search for Long-Acting Preparations. Research Monograph Series #4. DHEW Publication No. (ADM) 76-296 1976, National Institute on Drug Abuse, Rockville, Maryland.
25. Willette R.E., Barnett G. Narcotic Antagonists: Naltrexone Pharmacochemistry and Sustained-Release Preparations. NIDA Research Monograph #28. DHEW Publication No. (ADM) 81-902 1981, National Institute on Drug Abuse, Rockville, Maryland.